FDA Approved Products
190 products with lifecycle intelligence, competitive pressure scores, and patent timelines.
IQIRVO
elafibranor
Growth
Ipsen
ORAL · TABLET
2024
NDA0/100
ITOVEBI
inavolisib
Growth
Roche
ORAL · TABLET
2024
SMNDA0/100
IVRA
melphalan hcl
Growth
INTRAVENOUS · SOLUTION
2023
NDA0/100
IZERVAY
avacincaptad pegol sodium
Growth
Astellas
INTRAVITREAL · SOLUTION
geographic atrophy (GA) secondary to age-related macular degeneration (AMD) ()
2023
NDA0/100
JOURNAVX
suzetrigine
Growth
Vertex Pharmaceuticals
ORAL · TABLET
2025
NDA0/100
LAZCLUZE
lazertinib
Growth
Johnson & Johnson
ORAL · TABLET
2024
SMNDA0/100
LEQSELVI
deuruxolitinib phosphate
Growth
PharmaIN
ORAL · TABLET
2024
NDA0/100
LIKMEZ
metronidazole oral
Growth
ORAL · SUSPENSION
acute intestinal amebiasis (amoebic dysentery)amebic liver abscess in adults+5
2023
NDA0/100
LIQREV
sildenafil citrate
Growth
ORAL · SUSPENSION
2023
NDA0/100
LITFULO
ritlecitinib
Growth
Pfizer
ORAL · CAPSULE
severe alopecia areata in adultsadolescents 12 years+1
2023
SMNDA0/100
LIVDELZI
seladelpar lysine
Growth
Gilead Sciences
ORAL · CAPSULE
primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adultsmonotherapy in patients unable to tolerate UDCA
2024
NDA0/100
LODOCO
colchicine tablets 0.5 mg
Growth
Agepha Pharma
ORAL · TABLET
myocardial infarction (MI)stroke+3
2023
NDA0/100
LUMISIGHT
pegulicianine
Growth
Lumicell
INTRAVENOUS · POWDER
breast cancer
2024
NDA0/100
LUMRYZ
sodium oxybate
Growth
ORAL · FOR SUSPENSION, EXTENDED RELEASE
cataplexyexcessive daytime sleepiness (EDS) in patients 7 years of age+1
2023
NDA0/100
MICAFUNGIN IN SODIUM CHLORIDE 0.9%
micafungin in sodium chloride
Growth
Baxter
INTRAVENOUS · SOLUTION
Acute Disseminated CandidiasisAbscesses in adult+6
2023
NDA0/100
MIEBO
perfluorohexyloctane
Growth
Bausch + Lomb
OPHTHALMIC · SOLUTION/DROPS
the signssymptoms of dry eye disease (DED)+1
2023
NDA0/100
MIUDELLA
copper
Growth
Sebela Pharmaceuticals
INTRAUTERINE · SYSTEM
pregnancy in females of reproductive potential for up to 3 years
2025
NDA0/100
MOTPOLY XR
lacosamide
Growth
ORAL · CAPSULE, EXTENDED RELEASE
partial-onset seizures in adults
2023
NDA0/100
MYDCOMBI
phenylephrine hydrochloride; tropicamide
Growth
OPHTHALMIC · SPRAY, METERED
2023
NDA0/100
MYHIBBIN
mycophenolate mofetil
Growth
R-Pharm US
ORAL · SUSPENSION
organ rejection in adultolder of allogeneic kidney+3
2024
NDA0/100
NEFFY
epinephrine
Growth
ARS Pharmaceuticals
NASAL · SPRAY
2024
NDA0/100
OGSIVEO
nirogacestat
Growth
SpringWorks Therapeutics
ORAL · TABLET
2023
SMNDA0/100
OHTUVAYRE
ensifentrine
Growth
Verona Pharma
INHALATION · SUSPENSION
2024
NDA0/100
OJEMDA
tovorafenib
Growth
Day One Biopharmaceuticals
ORAL · TABLET
2024
SMNDA0/100